02 Fasting IRI (μU/mL) 7.64 ± 1.48 7.83 ± 1.65 0.94 Fasting glucagon (pg/mL) 72.3 ± 7.1 79.9 ± 6.6 0.45 AUC0–2h glucose (mmol/L·h) 20.50 ± 1.23 25.32 ± 1.09 0.01 AUC0–2h IRI (μU/mL·h) 54.3 ± 11.5 35.8 ± 6.8 0.21 AUC0–2h glucagon (pg/mL·h) 149.8 ± 10.7 174.6 ± 15.7 0.21 Data are presented as mean ± standard error unless otherwise indicated AUC 0–2h area under the curve (AUC0–2h) during the meal tolerance test, BMI body mass index, HbA 1c glycated hemoglobin A1c, HOMA-IR homeostasis model assessment-insulin TPCA-1 clinical trial resistance, HOMA-β homeostasis model assessment-beta

cell function, IRI immune-reactive insulin aGroups based on median change in glucose AUC0–2h after the addition of vildagliptin Table 3 Comparison of glucose-related parameters at 6 months between glucose ΔAUC0–2h groups after addition of vildagliptin   1st (n = 8) (≤64 mg/dL)a 2nd (n = 7) (>64 mg/dL)a P value HbA1c selleck chemical (%) 6.93 ± 0.19* 6.58 ± 0.12* 0.18 HOMA-IR 2.39 ± 0.23 1.62 ± 0.24 0.04 HOMA-β 36.4 ± 3.9 39.7 ± 9.0 0.74 Fasting glucose concentration (mmol/L) 7.53 ± 0.8 6.62 ± 0.28* 0.04 Fasting IRI (μU/mL) 7.14 ± 0.66 5.65 ± 0.97 0.22 Glucagon pre-meal test (pg/mL) 72.6 ± 6.3 64.0 ± 5.2 0.32 AUC0–2h glucose (mmol/L·hr) 20.30 ± 0.99 19.13 ± 1.11* 0.45 AUC0–2h IRI (μU/mL·hr) 55.8 ± 12.5 30.7 ± 6.5 0.11 AUC0–2h glucagon (pg/mL·hr) 147.9 ± 11.0 133.4 ± 8.3* 0.32 ΔAUC0–2h glucose (mmol/L·hr) −0.20 ± 1.15 −6.18 ± 0.85 <0.01

ΔAUC0–2h IRI (μU/mL·hr) 1.54 ± 13.5 −5.1 ± 9.5 0.70 ΔAUC0–2h glucagon (pg/mL·hr) −1.9 ± 11.1 −41.2 ± 13.5* 0.04 AUC 0–2h area under the curve during the meal tolerance test, HbA 1c glycated hemoglobin A1c, HOMA-IR homeostasis model assessment-insulin resistance, HOMA-β homeostasis model assessment-beta cell function, IRI immune-reactive insulin, Casein kinase 1 ΔAUC 0–2h difference in AUC0–2h before and after addition of vildagliptin * P < 0.05 vs. before the addition of vildagliptin aGroups based on change in glucose AUC0–2h after the addition of vildagliptin 4 Discussion Our results show that vildagliptin significantly improved blood glucose levels after MTT, and suppressed paradoxical glucagon elevation, but did not affect insulin release.

These results support the use of MTT in clinical settings for evaluating interactions between blood glucose, IRI, and glucagon levels in response to treatment with DPP-4 inhibitors. The improvement in glucose levels after the addition of a DPP-4 inhibitor in this study was similar to that in previous reports [6–9]. Treatment with DPP-4 inhibitors enhances insulin secretion in both the fasting and the postprandial phases due to inhibition of incretin cleavage. Pooled data from 327 patients in clinical trials in Japan showed that fasting insulin levels decreased 0.26 ± 0.22 μU/L 12 weeks after treatment with vildagliptin (50 mg bid) from 8.00 ± 0.30 μU/L at baseline, but this difference was not statistically significant [10].